Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. [electronic resource]
Producer: 19990730Description: 1189-96 p. digitalISSN:- 1078-0432
- Adenocarcinoma -- drug therapy
- Animals
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Camptothecin -- administration & dosage
- Cell Cycle -- drug effects
- Colonic Neoplasms -- drug therapy
- Cross-Linking Reagents -- pharmacology
- DNA Adducts
- DNA Damage
- DNA, Neoplasm -- biosynthesis
- Drug Screening Assays, Antitumor
- Drug Synergism
- Enzyme Inhibitors -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Irinotecan
- Mammary Neoplasms, Experimental -- drug therapy
- Nucleic Acid Synthesis Inhibitors -- pharmacology
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- RNA, Neoplasm -- biosynthesis
- Topoisomerase I Inhibitors
- Tumor Cells, Cultured -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.